Objective
HER2+ breast cancer affects around 390.000 women annually worldwide (i.e. 3 patients every 4 minutes). Over the last decade, polychemotherapy and HER2-targeted therapies have improved patient´s survival; however, the reality is that most patients are cured with less intense, toxic, and costly drugs. Up to now, no diagnostic test existed to guide the optimal therapy for each patient. The 27-gene HER2DX test (TRL8) is a novel minimally invasive diagnostic tool which provides unprecedented predictive information for therapy optimization in early-stage HER2+ disease. The DEFINITIVE project will prospectively validate HER2DX`s clinical effectiveness, proving its ability to significantly i) reduce toxicities, ii) improve quality of life and ii) reduce direct and indirect costs, while maintaining efficacy endpoints and survival outcomes in patients with early HER2+ breast cancer.
DEFINITIVE will combine international experts in breast cancer from international reference hospitals, comprehensive cancer networks, regulatory, HTA and medical statistics experts, SMEs, policy makers, patient associations, living labs and medical society networks. DEFINITIVE consortium will conduct a pragmatic clinical trial across 44 centres in 7 European and associated countries to randomize 304 patients with stage II to IIIA HER2+ breast cancer, in a 1:1 manner, and to be treated with the result of the HER2DX test to guide treatment vs without the result of the test (treatment by physician´s choice according to local guidelines). The inclusion and exclusion criteria will be very broad to make sure that most patients can participate in the trial and the results could be generalized to the overall population treated in real-world settings. Beyond seeking the endorsement and implementation of HER2DX diagnostic test by clinical guidelines and healthcare systems, DEFINITIVE will boost the incorporation of affordable non-invasive diagnostic tools in the field of genomics and precision oncology.
This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics)”.
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
Topic(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
08036 Barcelona
Spain
See on map
Participants (15)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
08008 BARCELONA
See on map
75013 Paris
See on map
41061 MONCHENGLADBACH
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1190 WIEN
See on map
35122 Padova
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35128 Padova
See on map
20121 Milano
See on map
T12 YN60 Cork
See on map
52621 Ramat Gan
See on map
3062 PA Rotterdam
See on map
1090 Wien
See on map
08908 L'HOSPITALET DEL LLOBREGAT
See on map
20149 Milano
See on map
08036 BARCELONA
See on map
Partners (2)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1219 CHATELAINE 12
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6500 Bellinzona
See on map